hERG (Kv11.1) Liability and Cytotoxicity Counter-Screen by Fluorescence-Based Thallium Flux and CellTiter-Glo in HEK293 Cells

hERG arm: 10-point, half-log dose-response (30 µM to ~1 nM final) in technical triplicate across 3 biological replicates, with E-4031 (selective hERG blocker) as the reference inhibitor on every plate. Cytotoxicity arm: same 10-point dilution in parallel plates, 48 h compound exposure, technical triplicate, n=3, with staurosporine as a cytotoxic positive control. Cells seeded at 20,000/well (hERG, same-day flux) and 5,000/well (48 h viability). Plate columns randomized; vehicle (0.3% DMSO) on every plate.

BSL-1 cell culture in a Class II biosafety cabinet. Thallium salts are highly toxic (acute and cumulative poison) — handle thallium stimulus solutions with double nitrile gloves, in the hood, avoid skin contact and aerosols, and dispose of all thallium-containing waste as designated hazardous heavy-metal waste (never down the drain). Staurosporine and E-4031 are biologically potent — handle as hazardous. DMSO is a skin penetrant. Wear lab coat and safety glasses; segregate biohazard and chemical waste per EHS.

hERG positive control: E-4031 at a saturating concentration defines 100% channel block (maximal flux inhibition). Vehicle control (0.3% DMSO) defines 0% inhibition / full flux. A no-thallium-stimulus well defines the flux floor. Cytotoxicity positive control: staurosporine defines maximal kill (0% viability); medium-only and vehicle wells define 100% viability. A no-cell (blank) well defines luminescence background. Parental untransfected HEK293 in the flux assay controls for non-hERG thallium permeability.

Flux assays show a clear thallium-evoked fluorescence rise in vehicle wells; E-4031 fully suppresses it, giving Z' >= 0.5 and a >= 5-fold window. E-4031 hERG IC50 is typically low-nanomolar to ~100 nM in flux format. Clean leads show hERG IC50 > 10 µM (low risk) and CC50 > 10x their on-target potency. Viability curves are sigmoidal; staurosporine CC50 is sub-micromolar. A useful output is a hERG-safety margin = hERG IC50 / on-target EC50 (> 30 desirable).

• HEK293 cells stably expressing hERG (Kv11.1), mycoplasma-free
• Growth/selection medium: DMEM + 10% FBS + 1% pen/strep + selection antibiotic
• Thallium-flux dye kit (FluxOR-type, thallium-sensitive indicator + loading buffer + PowerLoad + probenecid)
• Thallium stimulation buffer: thallium sulfate + potassium-free chloride-free stimulus per kit
• E-4031 dihydrochloride, 10 mM (selective hERG reference blocker)
• Staurosporine, 1 mM (cytotoxicity positive control)
• CellTiter-Glo 2.0 reagent (ATP-based luminescent viability)
• Test compounds, 10 mM in DMSO (final DMSO 0.3%)
• Black, clear-bottom 384-well plates (flux) and white 384-well plates (viability)

To identify off-target cardiac and cytotoxic safety liabilities early in optimization by quantifying compound inhibition of the hERG (Kv11.1) potassium channel via a fluorescent thallium-flux surrogate assay and, in parallel, by measuring general cytotoxicity with an ATP-content viability assay. This counter-screen produces hERG IC50 and cytotoxicity CC50 values and a derived safety window relative to on-target potency, de-risking compounds before in vivo studies.

1. hERG: seed 20,000 hERG-HEK293 cells/well in 384-well black/clear plates; culture overnight at 37 C, 5% CO2.
2. Remove medium; load cells with thallium-sensitive dye + probenecid in loading buffer, 60 min at room temperature.
3. Add 10-point compound dilutions (or vehicle/E-4031); pre-incubate 20-30 min at RT.
4. On a fluorescence plate reader (FLIPR-type, kinetic), record baseline, then inject thallium stimulus and record the fluorescence rise for 2-3 min.
5. Cytotoxicity: seed 5,000 cells/well in white plates; next day add the 10-point compound series.
6. Incubate 48 h at 37 C, 5% CO2.
7. Equilibrate plate to RT; add CellTiter-Glo 2.0 (equal volume), shake 2 min, incubate 10 min.
8. Read luminescence (0.5 s integration).
9. Process flux slopes/amplitudes and viability RLU for curve fitting.

Independent variable: compound concentration (10 points, ~1 nM to 30 µM). Dependent variables: thallium-flux fluorescence slope/amplitude (hERG % inhibition) and CellTiter-Glo RLU (% viability). Controlled variables: cell seeding density, dye-loading time, probenecid concentration, compound pre-incubation time, thallium stimulus concentration, kinetic read window, DMSO concentration (0.3%), and 48 h exposure time for cytotoxicity.

Compounds that block the hERG channel pore will reduce thallium influx through hERG channels, producing a concentration-dependent decrease in the thallium-sensitive fluorescence signal. We hypothesize that hERG-blocking liabilities are independent of general cytotoxicity, so combining hERG IC50 with CC50 yields a safety margin; compounds with hERG IC50 within ~30-fold of their therapeutic potency, or with low CC50, are flagged as high-risk.

For hERG, compute the thallium-flux response per well as the slope or amplitude of the fluorescence increase (baseline-corrected); normalize to % inhibition using vehicle (0%) and E-4031 (100%). For cytotoxicity, normalize RLU to % viability using vehicle (100%) and no-cell/staurosporine (0%). Fit both to 4PL models in GraphPad Prism (or ScreenWorks/equivalent) to extract hERG IC50 and cytotoxicity CC50. Report each as geometric mean +/- 95% CI across n=3, and compute the safety margin.

1. No thallium-flux signal: dye not loaded or efflux too fast — include probenecid and confirm loading time/temperature. 2. E-4031 fails to block: hERG expression lost — re-check selection antibiotic and confirm channel each run. 3. Flat dose-response with cytotoxic compounds: apparent hERG block is actually cell death — overlay CC50 and exclude overlapping hits. 4. High well-to-well variability in flux: uneven seeding or reader timing — use consistent density and a fixed inject-to-read latency. 5. Compressed viability window: cells over-confluent at assay end — seed lower (5,000/well) for the 48 h endpoint.

Analyze on the log scale (pIC50, pCC50). Compare compound hERG pIC50 values to E-4031 and across the series by one-way ANOVA with Dunnett's/Tukey correction at alpha = 0.05. With n=3 biological replicates and typical pIC50 SD ~0.2 log, the design detects ~3-fold potency differences with >80% power. Apparent-cytotoxicity confounds in the flux assay are excluded by cross-referencing CC50 (flag any hERG 'hit' whose IC50 overlaps CC50). Plates require Z' >= 0.5.